Testing hormone shots to protect ovaries during lupus chemotherapy
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at whether a monthly/3-month hormone medicine (a “GnRH shot”) can help protect ovaries in people with lupus who are treated with cyclophosphamide. It also compares this to lupus patients who do not receive the ovarian-protecting shot, using questionnaires to track outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus (SLE) and are female
- You are under 40 years old when starting cyclophosphamide
- You must be getting cyclophosphamide (CYC) either alone or with leuprolide (a GnRH shot)
- If you are in the GnRH shot group, you received leuprolide either monthly or every 3 months
- You must not have a history of reproductive problems, infertility, or untreated sexually transmitted infections
- If you are in the control group, you have lupus but did not receive cyclophosphamide with or without a GnRH shot
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests two hormone-blocking injections (leuprolide and goserelin) to suppress ovarian function in premenopausal women with breast cancer. It aims to see how well these drugs work when taken with standard hormone pills.
This trial tests whether an immune-modulating drug can restart ovulation and improve fertility in women whose ovaries stopped working due to autoimmune disease. It is for women ages 18–38 with autoimmune premature ovarian insufficiency and certain antibodies.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
Hear when a new Systemic Lupus Erythematosus (Sle) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.